Question:
You are tasked with answering the user's question using the provided context, which includes financial statements (Income Statements, Balance Sheets, and Cash Flow Statements) and financial news articles in multiple languages (English, Chinese, Japanese, Spanish, and Greek). Please provide a detailed and well-supported answer based on the information available. Limit your response to 100 words or fewer. If you cannot answer the question or if no relevant evidence is found, write “None”.

Answer Format:
Answer: {Answer using the financial statement.}
News Evidence: {Verify your answer using quote(s) from the financial news. Write “None” if no news evidence is available.}
Context:
Financial Statements:
| Column 1                                                                                | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   |
|:-------------------------------------------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|
|                                                                                |            |            |            |            |            |            |            |            |
|                                                                                | 2024       | 2023       |            |            |            |            |            |            |
| Assets                                                                                |            |            |            |            |            |            |            |            |
| Current assets                                                                                |            |            |            |            |            |            |            |            |
| Cash and cash equivalents (Notes 1 and 2)                                                                    | $24,105    | 21,859     |            |            |            |            |            |            |
| Marketable securities (Notes 1 and 2)                                                                        | 417        | 1,068      |            |            |            |            |            |            |
| Accounts receivable trade, less allowances $167(2023, $166)                                                  | 14,842     | 14,873     |            |            |            |            |            |            |
| Inventories (Notes 1 and 3)                                                                                | 12,444     | 11,181     |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Prepaid expenses and other receivables                                                                       | 4,085      | 4,514      |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total current assets                                                                                | 55,893     | 53,495     |            |            |            |            |            |            |
| Property, plant and equipment, net (Notes 1 and 4)                                                           | 20,518     | 19,898     |            |            |            |            |            |            |
| Intangible assets, net (Notes 1 and 5)                                                                       | 37,618     | 34,175     |            |            |            |            |            |            |
| Goodwill (Notes 1 and 5)                                                                                | 44,200     | 36,558     |            |            |            |            |            |            |
| Deferred taxes on income (Note 8)                                                                            | 10,461     | 9,279      |            |            |            |            |            |            |
| Other assets                                                                                | 11,414     | 14,153     |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total assets                                                                                | $180,104   | 167,558    |            |            |            |            |            |            |
| Liabilities and Shareholders’ Equity                                                                         |            |            |            |            |            |            |            |            |
| Current liabilities                                                                                |            |            |            |            |            |            |            |            |
| Loans and notes payable (Note 7)                                                                             | $5,983     | 3,451      |            |            |            |            |            |            |
| Accounts payable                                                                                | 10,311     | 9,632      |            |            |            |            |            |            |
| Accrued liabilities                                                                                | 8,549      | 10,212     |            |            |            |            |            |            |
| Accrued rebates, returns and promotions                                                                      | 17,580     | 16,001     |            |            |            |            |            |            |
| Accrued compensation and employee related obligations                                                        | 4,126      | 3,993      |            |            |            |            |            |            |
| Accrued taxes on income (Note 8)                                                                             | 3,772      | 2,993      |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total current liabilities                                                                                | 50,321     | 46,282     |            |            |            |            |            |            |
| Long-term debt (Note 7)                                                                                | 30,651     | 25,881     |            |            |            |            |            |            |
| Deferred taxes on income (Note 8)                                                                            | 2,448      | 3,193      |            |            |            |            |            |            |
| Employee related obligations (Notes 9 and 10)                                                                | 7,255      | 7,149      |            |            |            |            |            |            |
| Long-term taxes payable (Note 1)                                                                             | 390        | 2,881      |            |            |            |            |            |            |
| Other liabilities                                                                                | 17,549     | 13,398     |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total liabilities                                                                                | 108,614    | 98,784     |            |            |            |            |            |            |
| Commitments and Contingencies (Note 19)                                                                      |            |            |            |            |            |            |            |            |
| Shareholders’ equity                                                                                |            |            |            |            |            |            |            |            |
| Preferred stock — without par value (authorized and unissued2,000,000shares)                                 | —          | —          |            |            |            |            |            |            |
| Common stock — par value $1.00per share (Note 12) (authorized4,320,000,000shares; issued3,119,843,000shares) | 3,120      | 3,120      |            |            |            |            |            |            |
| Accumulated other comprehensive income (loss) (Note 13)                                                      | (11,741)   | (12,527)   |            |            |            |            |            |            |
| Retained earnings and Additional-paid-in-capital                                                             | 155,791    | 153,843    |            |            |            |            |            |            |
| Less: common stock held in treasury, at cost (Note 12) (712,921,000shares and712,765,000shares)              | 75,680     | 75,662     |            |            |            |            |            |            |
| Total shareholders’ equity                                                                                | 71,490     | 68,774     |            |            |            |            |            |            |
| Total liabilities and shareholders’ equity                                                                   | $180,104   | 167,558    |            |            |            |            |            |            |

---

| Column 1                                                                                | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   |
|:------------------------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
|                                                                                | 2024       | 2023       | 2022       |            |            |            |            |            |             |             |             |
| Cash flows from operating activities                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Net earnings                                                                              | $14,066    | 35,153     | 17,941     |            |            |            |            |            |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |            |            |            |            |            |            |            |             |             |             |
| Depreciation and amortization of property and intangibles                                 | 7,339      | 7,486      | 6,970      |            |            |            |            |            |             |             |             |
| Stock based compensation                                                                  | 1,176      | 1,162      | 1,138      |            |            |            |            |            |             |             |             |
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
| Asset write-downs                                                                         | 405        | 1,295      | 1,216      |            |            |            |            |            |             |             |             |
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
| Charges for acquired in-process research and development assets                           | 1,841      | 483        | —          |            |            |            |            |            |             |             |             |
| Gain on Kenvue separation                                                                 | —          | (20,984)   | —          |            |            |            |            |            |             |             |             |
| Net gain on sale of assets/businesses                                                     | (226)      | (117)      | (380)      |            |            |            |            |            |             |             |             |
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
| Deferred tax provision                                                                    | (2,183)    | (4,194)    | (1,663)    |            |            |            |            |            |             |             |             |
| Credit losses and accounts receivable allowances                                          | 11         | —          | (17)       |            |            |            |            |            |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |            |            |            |            |            |            |            |             |             |             |
| Increase in accounts receivable                                                           | (406)      | (624)      | (1,290)    |            |            |            |            |            |             |             |             |
| Increase in inventories                                                                   | (1,128)    | (1,323)    | (2,527)    |            |            |            |            |            |             |             |             |
| Increase in accounts payable and accrued liabilities                                      | 1,621      | 2,346      | 1,098      |            |            |            |            |            |             |             |             |
| Decrease/(Increase) in other current and non-current assets                               | 1,717      | (3,480)    | 687        |            |            |            |            |            |             |             |             |
| Increase/(Decrease) in other current and non-current liabilities                          | 33         | 5,588      | (1,979)    |            |            |            |            |            |             |             |             |
| Net cash flows from operating activities                                                  | 24,266     | 22,791     | 21,194     |            |            |            |            |            |             |             |             |
| Cash flows from investing activities                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Additions to property, plant and equipment                                                | (4,424)    | (4,543)    | (4,009)    |            |            |            |            |            |             |             |             |
| Proceeds from the disposal of assets/businesses, net                                      | 675        | 358        | 543        |            |            |            |            |            |             |             |             |
| Acquisitions, net of cash acquired (Note 18)                                              | (15,146)   | —          | (17,652)   |            |            |            |            |            |             |             |             |
| Acquired in-process research and development assets (Note 18)                             | (1,783)    | (470)      | —          |            |            |            |            |            |             |             |             |
| Purchases of investments                                                                  | (1,726)    | (10,906)   | (32,384)   |            |            |            |            |            |             |             |             |
| Sales of investments                                                                      | 2,462      | 19,390     | 41,609     |            |            |            |            |            |             |             |             |
| Credit support agreements activity, net                                                   | 1,517      | (2,963)    | (249)      |            |            |            |            |            |             |             |             |
| Other (including capitalized licenses and milestones)                                     | (174)      | 12         | (229)      |            |            |            |            |            |             |             |             |
| Net cash (used by)/from investing activities                                              | (18,599)   | 878        | (12,371)   |            |            |            |            |            |             |             |             |
| Cash flows from financing activities                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Dividends to shareholders                                                                 | (11,823)   | (11,770)   | (11,682)   |            |            |            |            |            |             |             |             |
| Repurchase of common stock                                                                | (2,432)    | (5,054)    | (6,035)    |            |            |            |            |            |             |             |             |
| Proceeds from short-term debt                                                             | 15,277     | 13,743     | 16,134     |            |            |            |            |            |             |             |             |
| Repayment of short-term debt                                                              | (9,463)    | (22,973)   | (6,550)    |            |            |            |            |            |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       | 6,660      | —          | 2          |            |            |            |            |            |             |             |             |
| Repayment of long-term debt                                                               | (1,453)    | (1,551)    | (2,134)    |            |            |            |            |            |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 838        | 1,094      | 1,329      |            |            |            |            |            |             |             |             |
| Credit support agreements activity, net                                                   | 272        | (219)      | (28)       |            |            |            |            |            |             |             |             |

---

Johnson & Johnson and subsidiaries consolidated statements of earnings
(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)

|     |     |     |     |     |     |     |     |     |     |     |     |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|     |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     | 2024 |     |     | 2023 |     |     | 2022 |     |     |
| Sales to customers |     |     | $88,821 |     |     | 85,159 |     |     | 79,990 |     |     |
| Cost of products sold |     |     | 27,471 |     |     | 26,553 |     |     | 24,596 |     |     |
| Gross profit |     |     | 61,350 |     |     | 58,606 |     |     | 55,394 |     |     |
| Selling, marketing and administrative expenses |     |     | 22,869 |     |     | 21,512 |     |     | 20,246 |     |     |
| Research and development expense |     |     | 17,232 |     |     | 15,085 |     |     | 14,135 |     |     |
| In-process research and development impairments |     |     | 211 |     |     | 313 |     |     | 783 |     |     |
| Interest income |     |     | (1,332) |     |     | (1,261) |     |     | (490) |     |     |
| Interest expense, net of portion capitalized (Note 4) |     |     | 755 |     |     | 772 |     |     | 276 |     |     |
| Other (income) expense, net |     |     | 4,694 |     |     | 6,634 |     |     | 810 |     |     |
| Restructuring (Note 20) |     |     | 234 |     |     | 489 |     |     | 275 |     |     |
| Earnings before provision for taxes on income |     |     | 16,687 |     |     | 15,062 |     |     | 19,359 |     |     |
| Provision for taxes on income (Note 8) |     |     | 2,621 |     |     | 1,736 |     |     | 2,989 |     |     |
| Net earnings from continuing operations |     |     | 14,066 |     |     | 13,326 |     |     | 16,370 |     |     |
| Net earnings from discontinued operations, net of tax (Note 21) |     |     | —   |     |     | 21,827 |     |     | 1,571 |     |     |
| Net earnings |     |     | $14,066 |     |     | 35,153 |     |     | 17,941 |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Net earnings per share (Notes 1 and 15) |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Continuing operations - basic |     |     | $5.84 |     |     | 5.26 |     |     | 6.23 |     |     |
| Discontinued operations - basic |     |     | —   |     |     | 8.62 |     |     | 0.60 |     |     |
| Total net earnings per share - basic |     |     | $5.84 |     |     | 13.88 |     |     | 6.83 |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Continuing operations - diluted |     |     | $5.79 |     |     | 5.20 |     |     | 6.14 |     |     |
| Discontinued operations - diluted |     |     | —   |     |     | 8.52 |     |     | 0.59 |     |     |
| Total net earnings per share - diluted |     |     | $5.79 |     |     | 13.72 |     |     | 6.73 |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Average shares outstanding (Notes 1 and 15) |     |     |     |     |     |     |     |     |     |     |     |
| Basic |     |     | 2,407.3 |     |     | 2,533.5 |     |     | 2,625.2 |     |     |
| Diluted |     |     | 2,429.4 |     |     | 2,560.4 |     |     | 2,663.9 |     |     |

---

English News:
**Johnson & Johnson Reports Solid Financial Performance Amid Mixed Sales Dynamics** Johnson & Johnson has announced a 4.3% increase in worldwide sales for the fiscal year ending December 29, 2024, reaching a total of $88.8 billion. This growth was largely fueled by an 8.3% rise in U.S. sales, which amounted to $50.3 billion. However, international sales experienced a minor decline of 0.5%, totaling $38.5 billion. Key contributors to the sales growth include the company's Innovative Medicine and MedTech segments, which reported increases of 4.0% and 4.8%, respectively. The company's financial stability was underscored by its robust liquidity position, with cash and cash equivalents standing at $24.1 billion, up from $21.9 billion in the previous year. Operating cash flows also demonstrated strength, generating $24.3 billion compared to $22.8 billion in 2023. Despite these positive developments, Johnson & Johnson's net earnings from continuing operations for 2024 totaled $14.1 billion, with earnings per share reported at $5.84 on a basic basis and $5.79 on a diluted basis. The company's comprehensive income for the year stood at $14.85 billion, a noticeable decline from $30.41 billion in 2023. This decrease was influenced by a reduction in other comprehensive income elements. Overall, Johnson & Johnson’s financial performance reflects its ability to leverage domestic sales growth while managing challenges in international markets, maintaining a strong cash flow and liquidity position despite fluctuations in comprehensive income.

Chinese News:
抢抓中国市场机遇 跨国药企去年营收增长 近期，跨国药企2024年“成绩单”陆续出炉。整体来看，头部跨国药企呈现出营收增长、创新产品放量明显、精准并购加速发展等主要趋势。作为全球重要的医药市场之一，中国市场依然是各大药企争夺的焦点。 “药王”争霸 根据跨国药企公布的业绩情况来看，强生以总营收888.21亿美元蝉联第一，罗氏、默沙东、辉瑞分别以超过600亿美元的营收位列二、三、四名。艾伯维、阿斯利康、诺华紧随其后，营收均超500亿美元。百时美施贵宝（BMS）、礼来、赛诺菲、诺和诺德、葛兰素史克营收均超过400亿美元。 在跨国药企的竞争中，百亿美元的年销售额通常是单品进入全球重磅药物榜单的门槛。今年的“药王”争霸同样激烈。 司美格鲁肽的快速增长使该药物具备充足的想象空间。诺和诺德的司美格鲁肽系列产品（包括Ozempic、Rybelsus和Wegovy）在2024年成绩斐然，不负期待。诺和诺德2024年业绩报告显示，该药物总销售额达到292.96亿美元，同比增长38.43%，占诺和诺德营收总额的69.5%。其中，减肥用司美格鲁肽注射液Wegovy同比增幅达86%，增幅更为亮眼。 尽管如此，“药王”称号依然被K药以微弱优势“夺走”。 自2014年首次问世以来，默沙东的K药（Keytruda，帕博利珠单抗）已成为全球医药市场的一颗璀璨明星。历经十年的市场洗礼与科学验证，K药在销售业绩上屡创新高。 根据默沙东2024年业绩报告显示，该药物以18%的增长速度创收294.82亿美元，销售额约占默沙东全年总营收的46%。该药物在全球范围内获批了约40个适应症，在肿瘤治疗领域的主导地位稳固。数据显示，该药物上市十年来累计销售额高达1310亿美元。 赛诺菲的度普利尤单抗（Dupixent）在2024年的表现也值得关注。该药物是慢阻肺病领域第一款生物靶向制剂，2024年其年销售额达到130.72亿欧元（约141.79亿美元）的新高点，同比增长23.1%，成为目前最畅销的自免产品。 尽管辉瑞2024年全年实现总营收636.27亿美元（同比增长7%）未能挤进全球三甲，但公司的制药业务实现了626亿美元的营收，成为“2024年的全球制药营收一哥”。 辉瑞用一年时间就消化了“新冠悬崖”，重回增长轨道。新冠防治类药物依然为辉瑞贡献了超过110亿美元的销售额。此外，辉瑞与BMS共同研发的抗凝血药物，2024年的销售额达到了133亿美元，辉瑞分得的营收额为73.66亿美元。 尽管保住了全球第一大制药巨头的地位，辉瑞创新乏力的现象依然未改，公司多个产品面临专利悬崖，这也严重影响了公司在资本市场的表现，其市值远低于其他头部跨国药企。 而在TOP 10的跨国药企中，2024年营收同比增速最快的是礼来。 根据礼来公布的2024年业绩报告，公司实现营收450.43亿美元，同比增长32%；实现净利润105.9亿美元，同比增长102%。心血管代谢板块是礼来的核心业务，2024年该板块实现营收295.21亿美元，营收占比66%，主要得益于替尔泊肽的快速放量。 中国机遇 作为全球第二大医药市场，中国区的经营情况对大型跨国药企业绩的影响不言而喻。 阿斯利康2024年在中国区实现11%的两位数增长，以64.13亿美元（占其全球市场份额的12%）的收入在跨国药企中国区业绩比拼中独占鳌头。阿斯利康表示，中国区增长动力来自PARP抑制剂奥拉帕利Lynparza，2024年该药物卵巢癌适应证被纳入医保。该药物对应的新兴市场实现6.55亿美元的营收，同比增长30%，中国应是主要驱动力。 2024年，阿斯利康加大在中国的投入，宣布将在无锡新建一座小分子创新药物工厂。此外，2023年宣布在青岛建设吸入气雾剂生产供应基地的项目也在稳步推进中。 中国作为诺华全球第二大市场，2024年表现尤为突出，全年销售额39亿美元，同比增长21%，远超全球平均增速。诺华备受瞩目的核药Pluvicto在2024年收入达13.92亿美元，实现了42%的增长。2024年，诺华在中国提交了Pluvicto的上市申请，并于同年7月在中国正式启动了首个核药生产基地建设，投资约6亿元，预计2026年底建成投产。 赛诺菲2024年中国市场收入26.66亿欧元（约28.92亿美元），增长微微下滑（-0.5%）。公司于2024年12月，豪掷10亿欧元在北京设立了全新的生产制造基地，这是赛诺菲在中国最大的单笔投资。该工厂旨在提升胰岛素在中国本地端到端生产制药能力，重点服务中国本土糖尿病患者的胰岛素用药需求。 默沙东2024年中国区营收53.94亿美元（占其全球制药业务的9.4%），降幅接近20%，成为跨国药企中在中国区业绩降幅最大的一家。公司的四价/九价HPV疫苗佳达修2024年第四季度在中国市场收入下滑明显。此外，由于仿制药竞争，默沙东西格列汀和西格列汀二甲双胍在中国市场供应也出现减少。 默沙东表示，中国市场为佳达修提供了一个重要的长期机遇，公司将继续致力于并做好充分准备，以最大限度地发挥这一长期潜力。 有行业报告统计，2024年大型制药企业从外部授权引进的候选分子里，有1/3以上来自中国。行业人士认为，中国市场作为全球第二大医药市场，未来如何“在中国发现价值管线，在中国以外做价值兑现”，将极度考验跨国药企的眼力和魄力，中国市场也有望成为各企业的决胜要塞之一。

Japanese News:
ジョンソン・エンド・ジョンソン、2024年通期は増収も最終減益、売上高4％増の888億ドル、純利益60％減の140億ドル

Spanish News:
Johnson & Johnson (J&J) ha presentado sus resultados del cuarto trimestre de 2024, superando las previsiones de los analistas, aunque los beneficios cayeron ligeramente en comparación con el año anterior. La compañía, líder en productos farmacéuticos y dispositivos médicos, registró beneficios por acción (BPA) mejores de lo esperado, lo que provocó que las acciones subieran inicialmente un 1,9% en las operaciones previas a la apertura del mercado. Sin embargo, esas ganancias se desvanecieron y, al final, las acciones bajaron un 0,5% antes de la apertura. Resultados clave del cuarto trimestre: BPA ajustado: 2,04 dólares frente a 2,29 dólares interanuales (consenso de Bloomberg: 1,99 dólares) Ingresos: 22.520 millones de dólares, un aumento del 5,3 % interanual (estimación: 22.430 millones de dólares) Ventas de tecnología médica: 8.190 millones de dólares, un 6,7 % más interanual (estimación: 8.230 millones de dólares) Rendimiento de las ventas de medicamentos: Imbruvica: 731 millones de dólares, un 7,2 % menos interanual (estimación: 711,6 millones de dólares) Invega Sustenna: 1.060 millones de dólares, un 5,1 % más interanual (estimación: 1.030 millones de dólares) Darzalex: 3.080 millones de dólares, un 21 % más interanual (estimación: 3.020 millones de dólares) Erleada: 784 millones de dólares (estimación: 792,1 millones de dólares) Tremfya: 949 millones de dólares, un aumento del 4,3 % interanual (estimación: 1.050 millones de dólares) Remicade: 359 millones de dólares, una disminución del 16 % interanual (estimación: 371,8 millones de dólares) Stelara: 2.350 millones de dólares, una disminución del 15 % interanual (estimación: 2.400 millones de dólares) Zytiga: 135 millones de dólares, una disminución del 33 % interanual (estimación: 134,4 millones de dólares) Xarelto: 676 millones de dólares, un aumento del 29 % interanual (estimación: 512,4 millones de dólares) Simponi: 583 millones de dólares, un aumento del 16 % interanual (estimación: 502,7 millones de dólares) Perspectivas para 2025: Ingresos: 89.200 millones de dólares a 90.000 millones de dólares BPA operativo ajustado: 10,75 a 10,95 dólares BPA ajustada: 10,50 a 10,70 dólares Comentario sobre los beneficios: La compañía proyecta un crecimiento de las ventas operativas para 2025 del 2,5% al 3,5%. Estas proyecciones no incluyen el impacto de la adquisición de Intra-Cellular Therapies Inc. (ITCI), cuya compra podría añadir hasta 35 centavos por acción a las ganancias por acción ajustadas. Se espera que la adquisición, valorada en casi 15.000 millones de dólares, refuerce la presencia de J&J en el sector de la neurología. Las fuertes ventas de medicamentos contra el cáncer, como Darzalex, han ayudado a compensar la disminución de la demanda de tratamientos para la psoriasis, como Stelara, que enfrenta competencia de los genéricos. Desafíos legales y acuerdos pendientes: La empresa también está esperando la aprobación judicial de un acuerdo de 8.000 millones de dólares que resolvería miles de demandas relacionadas con el talco. A pesar de los desafíos, especialmente relacionados con las negociaciones de precios de medicamentos en los EE. UU., los ejecutivos de J&J han expresado un tono optimista sobre el futuro de la industria farmacéutica, señalando que políticas de apoyo a los fabricantes nacionales podrían beneficiar al sector.

Greek News:
Η Johnson & Johnson (J&J) συνεχίζει να επιδεικνύει ισχυρή οικονομική σταθερότητα και στρατηγική δέσμευση στην καινοτομία, όπως αποτυπώνεται στα οικονομικά στοιχεία του 2024. Η εταιρεία επένδυσε 17,2 δισεκατομμύρια δολάρια στην έρευνα και ανάπτυξη (R&D), υπογραμμίζοντας τη μακροπρόθεσμη στρατηγική της για τη δημιουργία προϊόντων που επιδρούν θετικά στην υγεία και ευημερία της ανθρωπότητας. Η εν λόγω επένδυση συνοδεύεται από ενεργές συνεργασίες που ενισχύουν την προστιθέμενη αξία και την επιστημονική πρόοδο. Αποτέλεσμα αυτής της στρατηγικής ήταν ότι τα νέα προϊόντα που κυκλοφόρησαν την τελευταία πενταετία αντιπροσώπευσαν περίπου το 25% των συνολικών πωλήσεων του 2024, στοιχείο που αναδεικνύει την εμπορική επιτυχία των επενδύσεων στην καινοτομία. Σε επίπεδο ρευστότητας, η J&J εμφάνισε αύξηση των μετρητών και των ισοδύναμων μετρητών, φθάνοντας τα 24,1 δισεκατομμύρια δολάρια στο τέλος του 2024, έναντι 21,9 δισεκατομμυρίων δολαρίων το 2023. Η εταιρεία διαχειρίζεται τα πλεονάζοντα διαθέσιμά της με συντηρητικό και προσεκτικό τρόπο, επενδύοντας σε καταθέσεις σε μεγάλες διεθνείς τράπεζες και σε αξιόπιστα μέσα χρηματαγοράς. Σύμφωνα με την επενδυτική της πολιτική, επιλέγει αποκλειστικά ιδρύματα με πιστοληπτική αξιολόγηση επενδυτικής βαθμίδας, γεγονός που διασφαλίζει την προστασία του κεφαλαίου και τη σταθερότητα της χρηματοοικονομικής της βάσης.

Question:
How does the company’s balance sheet reflect its financial health in terms of total amount of current assets and the ratio of total liability divided by total equity? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: How does the company’s balance sheet reflect its financial health in terms of total amount of current assets and the ratio of total liability divided by total equity? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.


Question:
You are tasked with answering the user's question using the provided context, which includes financial statements (Income Statements, Balance Sheets, and Cash Flow Statements) and financial news articles in multiple languages (English, Chinese, Japanese, Spanish, and Greek). Please provide a detailed and well-supported answer based on the information available. Limit your response to 100 words or fewer. If you cannot answer the question or if no relevant evidence is found, write “None”.

Answer Format:
Answer: {Answer using the financial statement.}
News Evidence: {Verify your answer using quote(s) from the financial news. Write “None” if no news evidence is available.}
Context:
Financial Statements:
| Column 1                                                                                | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   |
|:-------------------------------------------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|
|                                                                                |            |            |            |            |            |            |            |            |
|                                                                                | 2024       | 2023       |            |            |            |            |            |            |
| Assets                                                                                |            |            |            |            |            |            |            |            |
| Current assets                                                                                |            |            |            |            |            |            |            |            |
| Cash and cash equivalents (Notes 1 and 2)                                                                    | $24,105    | 21,859     |            |            |            |            |            |            |
| Marketable securities (Notes 1 and 2)                                                                        | 417        | 1,068      |            |            |            |            |            |            |
| Accounts receivable trade, less allowances $167(2023, $166)                                                  | 14,842     | 14,873     |            |            |            |            |            |            |
| Inventories (Notes 1 and 3)                                                                                | 12,444     | 11,181     |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Prepaid expenses and other receivables                                                                       | 4,085      | 4,514      |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total current assets                                                                                | 55,893     | 53,495     |            |            |            |            |            |            |
| Property, plant and equipment, net (Notes 1 and 4)                                                           | 20,518     | 19,898     |            |            |            |            |            |            |
| Intangible assets, net (Notes 1 and 5)                                                                       | 37,618     | 34,175     |            |            |            |            |            |            |
| Goodwill (Notes 1 and 5)                                                                                | 44,200     | 36,558     |            |            |            |            |            |            |
| Deferred taxes on income (Note 8)                                                                            | 10,461     | 9,279      |            |            |            |            |            |            |
| Other assets                                                                                | 11,414     | 14,153     |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total assets                                                                                | $180,104   | 167,558    |            |            |            |            |            |            |
| Liabilities and Shareholders’ Equity                                                                         |            |            |            |            |            |            |            |            |
| Current liabilities                                                                                |            |            |            |            |            |            |            |            |
| Loans and notes payable (Note 7)                                                                             | $5,983     | 3,451      |            |            |            |            |            |            |
| Accounts payable                                                                                | 10,311     | 9,632      |            |            |            |            |            |            |
| Accrued liabilities                                                                                | 8,549      | 10,212     |            |            |            |            |            |            |
| Accrued rebates, returns and promotions                                                                      | 17,580     | 16,001     |            |            |            |            |            |            |
| Accrued compensation and employee related obligations                                                        | 4,126      | 3,993      |            |            |            |            |            |            |
| Accrued taxes on income (Note 8)                                                                             | 3,772      | 2,993      |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total current liabilities                                                                                | 50,321     | 46,282     |            |            |            |            |            |            |
| Long-term debt (Note 7)                                                                                | 30,651     | 25,881     |            |            |            |            |            |            |
| Deferred taxes on income (Note 8)                                                                            | 2,448      | 3,193      |            |            |            |            |            |            |
| Employee related obligations (Notes 9 and 10)                                                                | 7,255      | 7,149      |            |            |            |            |            |            |
| Long-term taxes payable (Note 1)                                                                             | 390        | 2,881      |            |            |            |            |            |            |
| Other liabilities                                                                                | 17,549     | 13,398     |            |            |            |            |            |            |
|                                                                                |            |            |            |            |            |            |            |            |
| Total liabilities                                                                                | 108,614    | 98,784     |            |            |            |            |            |            |
| Commitments and Contingencies (Note 19)                                                                      |            |            |            |            |            |            |            |            |
| Shareholders’ equity                                                                                |            |            |            |            |            |            |            |            |
| Preferred stock — without par value (authorized and unissued2,000,000shares)                                 | —          | —          |            |            |            |            |            |            |
| Common stock — par value $1.00per share (Note 12) (authorized4,320,000,000shares; issued3,119,843,000shares) | 3,120      | 3,120      |            |            |            |            |            |            |
| Accumulated other comprehensive income (loss) (Note 13)                                                      | (11,741)   | (12,527)   |            |            |            |            |            |            |
| Retained earnings and Additional-paid-in-capital                                                             | 155,791    | 153,843    |            |            |            |            |            |            |
| Less: common stock held in treasury, at cost (Note 12) (712,921,000shares and712,765,000shares)              | 75,680     | 75,662     |            |            |            |            |            |            |
| Total shareholders’ equity                                                                                | 71,490     | 68,774     |            |            |            |            |            |            |
| Total liabilities and shareholders’ equity                                                                   | $180,104   | 167,558    |            |            |            |            |            |            |

---

| Column 1                                                                                | Column 2   | Column 3   | Column 4   | Column 5   | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   |
|:------------------------------------------------------------------------------------------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
|                                                                                | 2024       | 2023       | 2022       |            |            |            |            |            |             |             |             |
| Cash flows from operating activities                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Net earnings                                                                              | $14,066    | 35,153     | 17,941     |            |            |            |            |            |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |            |            |            |            |            |            |            |             |             |             |
| Depreciation and amortization of property and intangibles                                 | 7,339      | 7,486      | 6,970      |            |            |            |            |            |             |             |             |
| Stock based compensation                                                                  | 1,176      | 1,162      | 1,138      |            |            |            |            |            |             |             |             |
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
| Asset write-downs                                                                         | 405        | 1,295      | 1,216      |            |            |            |            |            |             |             |             |
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
| Charges for acquired in-process research and development assets                           | 1,841      | 483        | —          |            |            |            |            |            |             |             |             |
| Gain on Kenvue separation                                                                 | —          | (20,984)   | —          |            |            |            |            |            |             |             |             |
| Net gain on sale of assets/businesses                                                     | (226)      | (117)      | (380)      |            |            |            |            |            |             |             |             |
|                                                                                |            |            |            |            |            |            |            |            |             |             |             |
| Deferred tax provision                                                                    | (2,183)    | (4,194)    | (1,663)    |            |            |            |            |            |             |             |             |
| Credit losses and accounts receivable allowances                                          | 11         | —          | (17)       |            |            |            |            |            |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |            |            |            |            |            |            |            |             |             |             |
| Increase in accounts receivable                                                           | (406)      | (624)      | (1,290)    |            |            |            |            |            |             |             |             |
| Increase in inventories                                                                   | (1,128)    | (1,323)    | (2,527)    |            |            |            |            |            |             |             |             |
| Increase in accounts payable and accrued liabilities                                      | 1,621      | 2,346      | 1,098      |            |            |            |            |            |             |             |             |
| Decrease/(Increase) in other current and non-current assets                               | 1,717      | (3,480)    | 687        |            |            |            |            |            |             |             |             |
| Increase/(Decrease) in other current and non-current liabilities                          | 33         | 5,588      | (1,979)    |            |            |            |            |            |             |             |             |
| Net cash flows from operating activities                                                  | 24,266     | 22,791     | 21,194     |            |            |            |            |            |             |             |             |
| Cash flows from investing activities                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Additions to property, plant and equipment                                                | (4,424)    | (4,543)    | (4,009)    |            |            |            |            |            |             |             |             |
| Proceeds from the disposal of assets/businesses, net                                      | 675        | 358        | 543        |            |            |            |            |            |             |             |             |
| Acquisitions, net of cash acquired (Note 18)                                              | (15,146)   | —          | (17,652)   |            |            |            |            |            |             |             |             |
| Acquired in-process research and development assets (Note 18)                             | (1,783)    | (470)      | —          |            |            |            |            |            |             |             |             |
| Purchases of investments                                                                  | (1,726)    | (10,906)   | (32,384)   |            |            |            |            |            |             |             |             |
| Sales of investments                                                                      | 2,462      | 19,390     | 41,609     |            |            |            |            |            |             |             |             |
| Credit support agreements activity, net                                                   | 1,517      | (2,963)    | (249)      |            |            |            |            |            |             |             |             |
| Other (including capitalized licenses and milestones)                                     | (174)      | 12         | (229)      |            |            |            |            |            |             |             |             |
| Net cash (used by)/from investing activities                                              | (18,599)   | 878        | (12,371)   |            |            |            |            |            |             |             |             |
| Cash flows from financing activities                                                      |            |            |            |            |            |            |            |            |             |             |             |
| Dividends to shareholders                                                                 | (11,823)   | (11,770)   | (11,682)   |            |            |            |            |            |             |             |             |
| Repurchase of common stock                                                                | (2,432)    | (5,054)    | (6,035)    |            |            |            |            |            |             |             |             |
| Proceeds from short-term debt                                                             | 15,277     | 13,743     | 16,134     |            |            |            |            |            |             |             |             |
| Repayment of short-term debt                                                              | (9,463)    | (22,973)   | (6,550)    |            |            |            |            |            |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       | 6,660      | —          | 2          |            |            |            |            |            |             |             |             |
| Repayment of long-term debt                                                               | (1,453)    | (1,551)    | (2,134)    |            |            |            |            |            |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 838        | 1,094      | 1,329      |            |            |            |            |            |             |             |             |
| Credit support agreements activity, net                                                   | 272        | (219)      | (28)       |            |            |            |            |            |             |             |             |

---

Johnson & Johnson and subsidiaries consolidated statements of earnings
(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)

|     |     |     |     |     |     |     |     |     |     |     |     |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|     |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     | 2024 |     |     | 2023 |     |     | 2022 |     |     |
| Sales to customers |     |     | $88,821 |     |     | 85,159 |     |     | 79,990 |     |     |
| Cost of products sold |     |     | 27,471 |     |     | 26,553 |     |     | 24,596 |     |     |
| Gross profit |     |     | 61,350 |     |     | 58,606 |     |     | 55,394 |     |     |
| Selling, marketing and administrative expenses |     |     | 22,869 |     |     | 21,512 |     |     | 20,246 |     |     |
| Research and development expense |     |     | 17,232 |     |     | 15,085 |     |     | 14,135 |     |     |
| In-process research and development impairments |     |     | 211 |     |     | 313 |     |     | 783 |     |     |
| Interest income |     |     | (1,332) |     |     | (1,261) |     |     | (490) |     |     |
| Interest expense, net of portion capitalized (Note 4) |     |     | 755 |     |     | 772 |     |     | 276 |     |     |
| Other (income) expense, net |     |     | 4,694 |     |     | 6,634 |     |     | 810 |     |     |
| Restructuring (Note 20) |     |     | 234 |     |     | 489 |     |     | 275 |     |     |
| Earnings before provision for taxes on income |     |     | 16,687 |     |     | 15,062 |     |     | 19,359 |     |     |
| Provision for taxes on income (Note 8) |     |     | 2,621 |     |     | 1,736 |     |     | 2,989 |     |     |
| Net earnings from continuing operations |     |     | 14,066 |     |     | 13,326 |     |     | 16,370 |     |     |
| Net earnings from discontinued operations, net of tax (Note 21) |     |     | —   |     |     | 21,827 |     |     | 1,571 |     |     |
| Net earnings |     |     | $14,066 |     |     | 35,153 |     |     | 17,941 |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Net earnings per share (Notes 1 and 15) |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Continuing operations - basic |     |     | $5.84 |     |     | 5.26 |     |     | 6.23 |     |     |
| Discontinued operations - basic |     |     | —   |     |     | 8.62 |     |     | 0.60 |     |     |
| Total net earnings per share - basic |     |     | $5.84 |     |     | 13.88 |     |     | 6.83 |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Continuing operations - diluted |     |     | $5.79 |     |     | 5.20 |     |     | 6.14 |     |     |
| Discontinued operations - diluted |     |     | —   |     |     | 8.52 |     |     | 0.59 |     |     |
| Total net earnings per share - diluted |     |     | $5.79 |     |     | 13.72 |     |     | 6.73 |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |
| Average shares outstanding (Notes 1 and 15) |     |     |     |     |     |     |     |     |     |     |     |
| Basic |     |     | 2,407.3 |     |     | 2,533.5 |     |     | 2,625.2 |     |     |
| Diluted |     |     | 2,429.4 |     |     | 2,560.4 |     |     | 2,663.9 |     |     |

---

English News:
**Johnson & Johnson Reports Solid Financial Performance Amid Mixed Sales Dynamics** Johnson & Johnson has announced a 4.3% increase in worldwide sales for the fiscal year ending December 29, 2024, reaching a total of $88.8 billion. This growth was largely fueled by an 8.3% rise in U.S. sales, which amounted to $50.3 billion. However, international sales experienced a minor decline of 0.5%, totaling $38.5 billion. Key contributors to the sales growth include the company's Innovative Medicine and MedTech segments, which reported increases of 4.0% and 4.8%, respectively. The company's financial stability was underscored by its robust liquidity position, with cash and cash equivalents standing at $24.1 billion, up from $21.9 billion in the previous year. Operating cash flows also demonstrated strength, generating $24.3 billion compared to $22.8 billion in 2023. Despite these positive developments, Johnson & Johnson's net earnings from continuing operations for 2024 totaled $14.1 billion, with earnings per share reported at $5.84 on a basic basis and $5.79 on a diluted basis. The company's comprehensive income for the year stood at $14.85 billion, a noticeable decline from $30.41 billion in 2023. This decrease was influenced by a reduction in other comprehensive income elements. Overall, Johnson & Johnson’s financial performance reflects its ability to leverage domestic sales growth while managing challenges in international markets, maintaining a strong cash flow and liquidity position despite fluctuations in comprehensive income.

Chinese News:
抢抓中国市场机遇 跨国药企去年营收增长 近期，跨国药企2024年“成绩单”陆续出炉。整体来看，头部跨国药企呈现出营收增长、创新产品放量明显、精准并购加速发展等主要趋势。作为全球重要的医药市场之一，中国市场依然是各大药企争夺的焦点。 “药王”争霸 根据跨国药企公布的业绩情况来看，强生以总营收888.21亿美元蝉联第一，罗氏、默沙东、辉瑞分别以超过600亿美元的营收位列二、三、四名。艾伯维、阿斯利康、诺华紧随其后，营收均超500亿美元。百时美施贵宝（BMS）、礼来、赛诺菲、诺和诺德、葛兰素史克营收均超过400亿美元。 在跨国药企的竞争中，百亿美元的年销售额通常是单品进入全球重磅药物榜单的门槛。今年的“药王”争霸同样激烈。 司美格鲁肽的快速增长使该药物具备充足的想象空间。诺和诺德的司美格鲁肽系列产品（包括Ozempic、Rybelsus和Wegovy）在2024年成绩斐然，不负期待。诺和诺德2024年业绩报告显示，该药物总销售额达到292.96亿美元，同比增长38.43%，占诺和诺德营收总额的69.5%。其中，减肥用司美格鲁肽注射液Wegovy同比增幅达86%，增幅更为亮眼。 尽管如此，“药王”称号依然被K药以微弱优势“夺走”。 自2014年首次问世以来，默沙东的K药（Keytruda，帕博利珠单抗）已成为全球医药市场的一颗璀璨明星。历经十年的市场洗礼与科学验证，K药在销售业绩上屡创新高。 根据默沙东2024年业绩报告显示，该药物以18%的增长速度创收294.82亿美元，销售额约占默沙东全年总营收的46%。该药物在全球范围内获批了约40个适应症，在肿瘤治疗领域的主导地位稳固。数据显示，该药物上市十年来累计销售额高达1310亿美元。 赛诺菲的度普利尤单抗（Dupixent）在2024年的表现也值得关注。该药物是慢阻肺病领域第一款生物靶向制剂，2024年其年销售额达到130.72亿欧元（约141.79亿美元）的新高点，同比增长23.1%，成为目前最畅销的自免产品。 尽管辉瑞2024年全年实现总营收636.27亿美元（同比增长7%）未能挤进全球三甲，但公司的制药业务实现了626亿美元的营收，成为“2024年的全球制药营收一哥”。 辉瑞用一年时间就消化了“新冠悬崖”，重回增长轨道。新冠防治类药物依然为辉瑞贡献了超过110亿美元的销售额。此外，辉瑞与BMS共同研发的抗凝血药物，2024年的销售额达到了133亿美元，辉瑞分得的营收额为73.66亿美元。 尽管保住了全球第一大制药巨头的地位，辉瑞创新乏力的现象依然未改，公司多个产品面临专利悬崖，这也严重影响了公司在资本市场的表现，其市值远低于其他头部跨国药企。 而在TOP 10的跨国药企中，2024年营收同比增速最快的是礼来。 根据礼来公布的2024年业绩报告，公司实现营收450.43亿美元，同比增长32%；实现净利润105.9亿美元，同比增长102%。心血管代谢板块是礼来的核心业务，2024年该板块实现营收295.21亿美元，营收占比66%，主要得益于替尔泊肽的快速放量。 中国机遇 作为全球第二大医药市场，中国区的经营情况对大型跨国药企业绩的影响不言而喻。 阿斯利康2024年在中国区实现11%的两位数增长，以64.13亿美元（占其全球市场份额的12%）的收入在跨国药企中国区业绩比拼中独占鳌头。阿斯利康表示，中国区增长动力来自PARP抑制剂奥拉帕利Lynparza，2024年该药物卵巢癌适应证被纳入医保。该药物对应的新兴市场实现6.55亿美元的营收，同比增长30%，中国应是主要驱动力。 2024年，阿斯利康加大在中国的投入，宣布将在无锡新建一座小分子创新药物工厂。此外，2023年宣布在青岛建设吸入气雾剂生产供应基地的项目也在稳步推进中。 中国作为诺华全球第二大市场，2024年表现尤为突出，全年销售额39亿美元，同比增长21%，远超全球平均增速。诺华备受瞩目的核药Pluvicto在2024年收入达13.92亿美元，实现了42%的增长。2024年，诺华在中国提交了Pluvicto的上市申请，并于同年7月在中国正式启动了首个核药生产基地建设，投资约6亿元，预计2026年底建成投产。 赛诺菲2024年中国市场收入26.66亿欧元（约28.92亿美元），增长微微下滑（-0.5%）。公司于2024年12月，豪掷10亿欧元在北京设立了全新的生产制造基地，这是赛诺菲在中国最大的单笔投资。该工厂旨在提升胰岛素在中国本地端到端生产制药能力，重点服务中国本土糖尿病患者的胰岛素用药需求。 默沙东2024年中国区营收53.94亿美元（占其全球制药业务的9.4%），降幅接近20%，成为跨国药企中在中国区业绩降幅最大的一家。公司的四价/九价HPV疫苗佳达修2024年第四季度在中国市场收入下滑明显。此外，由于仿制药竞争，默沙东西格列汀和西格列汀二甲双胍在中国市场供应也出现减少。 默沙东表示，中国市场为佳达修提供了一个重要的长期机遇，公司将继续致力于并做好充分准备，以最大限度地发挥这一长期潜力。 有行业报告统计，2024年大型制药企业从外部授权引进的候选分子里，有1/3以上来自中国。行业人士认为，中国市场作为全球第二大医药市场，未来如何“在中国发现价值管线，在中国以外做价值兑现”，将极度考验跨国药企的眼力和魄力，中国市场也有望成为各企业的决胜要塞之一。

Japanese News:
ジョンソン・エンド・ジョンソン、2024年通期は増収も最終減益、売上高4％増の888億ドル、純利益60％減の140億ドル

Spanish News:
Johnson & Johnson (J&J) ha presentado sus resultados del cuarto trimestre de 2024, superando las previsiones de los analistas, aunque los beneficios cayeron ligeramente en comparación con el año anterior. La compañía, líder en productos farmacéuticos y dispositivos médicos, registró beneficios por acción (BPA) mejores de lo esperado, lo que provocó que las acciones subieran inicialmente un 1,9% en las operaciones previas a la apertura del mercado. Sin embargo, esas ganancias se desvanecieron y, al final, las acciones bajaron un 0,5% antes de la apertura. Resultados clave del cuarto trimestre: BPA ajustado: 2,04 dólares frente a 2,29 dólares interanuales (consenso de Bloomberg: 1,99 dólares) Ingresos: 22.520 millones de dólares, un aumento del 5,3 % interanual (estimación: 22.430 millones de dólares) Ventas de tecnología médica: 8.190 millones de dólares, un 6,7 % más interanual (estimación: 8.230 millones de dólares) Rendimiento de las ventas de medicamentos: Imbruvica: 731 millones de dólares, un 7,2 % menos interanual (estimación: 711,6 millones de dólares) Invega Sustenna: 1.060 millones de dólares, un 5,1 % más interanual (estimación: 1.030 millones de dólares) Darzalex: 3.080 millones de dólares, un 21 % más interanual (estimación: 3.020 millones de dólares) Erleada: 784 millones de dólares (estimación: 792,1 millones de dólares) Tremfya: 949 millones de dólares, un aumento del 4,3 % interanual (estimación: 1.050 millones de dólares) Remicade: 359 millones de dólares, una disminución del 16 % interanual (estimación: 371,8 millones de dólares) Stelara: 2.350 millones de dólares, una disminución del 15 % interanual (estimación: 2.400 millones de dólares) Zytiga: 135 millones de dólares, una disminución del 33 % interanual (estimación: 134,4 millones de dólares) Xarelto: 676 millones de dólares, un aumento del 29 % interanual (estimación: 512,4 millones de dólares) Simponi: 583 millones de dólares, un aumento del 16 % interanual (estimación: 502,7 millones de dólares) Perspectivas para 2025: Ingresos: 89.200 millones de dólares a 90.000 millones de dólares BPA operativo ajustado: 10,75 a 10,95 dólares BPA ajustada: 10,50 a 10,70 dólares Comentario sobre los beneficios: La compañía proyecta un crecimiento de las ventas operativas para 2025 del 2,5% al 3,5%. Estas proyecciones no incluyen el impacto de la adquisición de Intra-Cellular Therapies Inc. (ITCI), cuya compra podría añadir hasta 35 centavos por acción a las ganancias por acción ajustadas. Se espera que la adquisición, valorada en casi 15.000 millones de dólares, refuerce la presencia de J&J en el sector de la neurología. Las fuertes ventas de medicamentos contra el cáncer, como Darzalex, han ayudado a compensar la disminución de la demanda de tratamientos para la psoriasis, como Stelara, que enfrenta competencia de los genéricos. Desafíos legales y acuerdos pendientes: La empresa también está esperando la aprobación judicial de un acuerdo de 8.000 millones de dólares que resolvería miles de demandas relacionadas con el talco. A pesar de los desafíos, especialmente relacionados con las negociaciones de precios de medicamentos en los EE. UU., los ejecutivos de J&J han expresado un tono optimista sobre el futuro de la industria farmacéutica, señalando que políticas de apoyo a los fabricantes nacionales podrían beneficiar al sector.

Greek News:
Η Johnson & Johnson (J&J) συνεχίζει να επιδεικνύει ισχυρή οικονομική σταθερότητα και στρατηγική δέσμευση στην καινοτομία, όπως αποτυπώνεται στα οικονομικά στοιχεία του 2024. Η εταιρεία επένδυσε 17,2 δισεκατομμύρια δολάρια στην έρευνα και ανάπτυξη (R&D), υπογραμμίζοντας τη μακροπρόθεσμη στρατηγική της για τη δημιουργία προϊόντων που επιδρούν θετικά στην υγεία και ευημερία της ανθρωπότητας. Η εν λόγω επένδυση συνοδεύεται από ενεργές συνεργασίες που ενισχύουν την προστιθέμενη αξία και την επιστημονική πρόοδο. Αποτέλεσμα αυτής της στρατηγικής ήταν ότι τα νέα προϊόντα που κυκλοφόρησαν την τελευταία πενταετία αντιπροσώπευσαν περίπου το 25% των συνολικών πωλήσεων του 2024, στοιχείο που αναδεικνύει την εμπορική επιτυχία των επενδύσεων στην καινοτομία. Σε επίπεδο ρευστότητας, η J&J εμφάνισε αύξηση των μετρητών και των ισοδύναμων μετρητών, φθάνοντας τα 24,1 δισεκατομμύρια δολάρια στο τέλος του 2024, έναντι 21,9 δισεκατομμυρίων δολαρίων το 2023. Η εταιρεία διαχειρίζεται τα πλεονάζοντα διαθέσιμά της με συντηρητικό και προσεκτικό τρόπο, επενδύοντας σε καταθέσεις σε μεγάλες διεθνείς τράπεζες και σε αξιόπιστα μέσα χρηματαγοράς. Σύμφωνα με την επενδυτική της πολιτική, επιλέγει αποκλειστικά ιδρύματα με πιστοληπτική αξιολόγηση επενδυτικής βαθμίδας, γεγονός που διασφαλίζει την προστασία του κεφαλαίου και τη σταθερότητα της χρηματοοικονομικής της βάσης.

Question:
Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.